Which has higher earnings & valuation, KALA or BMRA?

Biomerica has higher revenue and earnings than KALA BIO. Biomerica is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A Biomerica $4.33M 1.19 -$4.97M -$0.89 N/A

Is KALA or BMRA more profitable?

KALA BIO has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Biomerica's return on equity of -98.14% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% Biomerica -96.49% -98.14% -70.42%

Do analysts recommend BMRA or ZIVO?

Biomerica currently has a consensus target price of $9.00, suggesting a potential upside of 442.17%. Given Biomerica's stronger consensus rating and higher probable upside, equities research analysts plainly believe Biomerica is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, BMRA or LGVN?

Biomerica has higher revenue and earnings than Longeveron. Biomerica is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomerica $4.33M 1.19 -$4.97M -$0.89 N/A Longeveron $1.20M 15.73 -$22.70M -$1.13 N/A

Is BMRA or LGVN more profitable?

Biomerica has a net margin of -96.49% compared to Longeveron's net margin of -1,844.49%. Biomerica's return on equity of -98.14% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Biomerica -96.49% -98.14% -70.42% Longeveron -1,844.49% -202.41% -140.67%

Which has better valuation & earnings, BMRA or LPCN?

Biomerica has higher revenue and earnings than Lipocine. Biomerica is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomerica $4.33M 1.19 -$4.97M -$0.89 N/A Lipocine $1.98M 9.03 -$9.63M -$1.88 N/A

Is BMRA or LPCN more profitable?

Biomerica has a net margin of -96.49% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Biomerica's return on equity. Company Net Margins Return on Equity Return on Assets Biomerica -96.49% -98.14% -70.42% Lipocine -571.18% -66.70% -59.39%

Biomerica (BMRA) Competitors

$1.66 +0.06 (+3.75%)

As of 10:21 AM Eastern

Compare

BMRA vs. ATOS, KALA, ZIVO, LGVN, and LPCN

Should you buy Biomerica stock or one of its competitors? MarketBeat compares Biomerica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biomerica include Atossa Genetics (ATOS), KALA BIO (KALA), ZIVO Bioscience (ZIVO), Longeveron (LGVN), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry.

How does Biomerica compare to Atossa Genetics?

Biomerica (NASDAQ:BMRA) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Biomerica currently has a consensus target price of $9.00, suggesting a potential upside of 442.17%. Atossa Genetics has a consensus target price of $20.33, suggesting a potential upside of 692.10%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Atossa Genetics had 1 more articles in the media than Biomerica. MarketBeat recorded 1 mentions for Atossa Genetics and 0 mentions for Biomerica. Biomerica's average media sentiment score of 0.00 equaled Atossa Genetics'average media sentiment score.

Company	Overall Sentiment
Biomerica	Neutral
Atossa Genetics	Neutral

Atossa Genetics has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Atossa Genetics' return on equity of -84.91% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
Atossa Genetics	N/A	-84.91%	-72.36%

Biomerica has higher revenue and earnings than Atossa Genetics. Biomerica is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$4.33M	1.19	-$4.97M	-$0.89	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

Biomerica has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

Summary

Atossa Genetics beats Biomerica on 8 of the 14 factors compared between the two stocks.

How does Biomerica compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by company insiders. Comparatively, 18.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

KALA BIO has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Biomerica's return on equity of -98.14% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
Biomerica	-96.49%	-98.14%	-70.42%

KALA BIO has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market. Comparatively, Biomerica has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

KALA BIO presently has a consensus target price of $1,158.33, indicating a potential upside of 150,921.30%. Biomerica has a consensus target price of $9.00, indicating a potential upside of 442.17%. Given KALA BIO's stronger consensus rating and higher probable upside, equities analysts clearly believe KALA BIO is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biomerica has higher revenue and earnings than KALA BIO. Biomerica is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
Biomerica	$4.33M	1.19	-$4.97M	-$0.89	N/A

In the previous week, KALA BIO had 1 more articles in the media than Biomerica. MarketBeat recorded 1 mentions for KALA BIO and 0 mentions for Biomerica. KALA BIO's average media sentiment score of 0.98 beat Biomerica's score of 0.00 indicating that KALA BIO is being referred to more favorably in the media.

Company	Overall Sentiment
KALA BIO	Positive
Biomerica	Neutral

Summary

KALA BIO beats Biomerica on 8 of the 15 factors compared between the two stocks.

How does Biomerica compare to ZIVO Bioscience?

Biomerica (NASDAQ:BMRA) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Biomerica currently has a consensus target price of $9.00, suggesting a potential upside of 442.17%. Given Biomerica's stronger consensus rating and higher probable upside, equities research analysts plainly believe Biomerica is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZIVO Bioscience has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. ZIVO Bioscience's return on equity of 0.00% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
ZIVO Bioscience	N/A	N/A	-2,240.92%

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Biomerica has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$4.33M	1.19	-$4.97M	-$0.89	N/A
ZIVO Bioscience	$15.85K	1,147.37	-$7.78M	-$1.71	N/A

In the previous week, Biomerica's average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Biomerica	Neutral
ZIVO Bioscience	Neutral

Biomerica has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market.

Summary

Biomerica beats ZIVO Bioscience on 8 of the 13 factors compared between the two stocks.

How does Biomerica compare to Longeveron?

Biomerica (NASDAQ:BMRA) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

In the previous week, Longeveron had 2 more articles in the media than Biomerica. MarketBeat recorded 2 mentions for Longeveron and 0 mentions for Biomerica. Longeveron's average media sentiment score of 0.61 beat Biomerica's score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.

Company	Overall Sentiment
Biomerica	Neutral
Longeveron	Positive

Biomerica presently has a consensus price target of $9.00, indicating a potential upside of 442.17%. Longeveron has a consensus price target of $5.50, indicating a potential upside of 807.59%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Biomerica has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, suggesting that its share price is 135% less volatile than the broader market.

Biomerica has a net margin of -96.49% compared to Longeveron's net margin of -1,844.49%. Biomerica's return on equity of -98.14% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
Longeveron	-1,844.49%	-202.41%	-140.67%

Biomerica has higher revenue and earnings than Longeveron. Biomerica is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$4.33M	1.19	-$4.97M	-$0.89	N/A
Longeveron	$1.20M	15.73	-$22.70M	-$1.13	N/A

Summary

Biomerica beats Longeveron on 9 of the 16 factors compared between the two stocks.

How does Biomerica compare to Lipocine?

Biomerica (NASDAQ:BMRA) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Biomerica has a net margin of -96.49% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
Lipocine	-571.18%	-66.70%	-59.39%

Biomerica has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

In the previous week, Lipocine had 2 more articles in the media than Biomerica. MarketBeat recorded 2 mentions for Lipocine and 0 mentions for Biomerica. Lipocine's average media sentiment score of 0.34 beat Biomerica's score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.

Company	Overall Sentiment
Biomerica	Neutral
Lipocine	Neutral

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 4.7% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Biomerica has higher revenue and earnings than Lipocine. Biomerica is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$4.33M	1.19	-$4.97M	-$0.89	N/A
Lipocine	$1.98M	9.03	-$9.63M	-$1.88	N/A

Biomerica presently has a consensus price target of $9.00, suggesting a potential upside of 442.17%. Lipocine has a consensus price target of $15.00, suggesting a potential upside of 590.93%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Lipocine beats Biomerica on 10 of the 16 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMRA vs. The Competition

Export

Metric	Biomerica	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.11M	$3.06B	$6.80B	$12.37B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-1.87	20.36	27.09	24.07
Price / Sales	1.19	346.34	520.26	91.86
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	1.03	4.23	10.64	6.20
Net Income	-$4.97M	$65.94M	$3.60B	$331.63M
7 Day Performance	1.84%	-2.16%	-1.41%	-1.54%
1 Month Performance	-7.26%	-0.50%	0.97%	-1.17%
1 Year Performance	-52.57%	16.28%	24.23%	17.81%

Biomerica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMRA Biomerica	2.0641 of 5 stars	$1.66 +3.8%	$9.00 +442.2%	-52.9%	$5.11M	$4.33M	N/A	60
ATOS Atossa Genetics	2.0329 of 5 stars	$2.26 -5.8%	$20.33 +799.7%	-80.3%	$20.67M	N/A	N/A	8	News Coverage
KALA KALA BIO	2.3743 of 5 stars	$0.96 -11.6%	$1,158.33 +120,146.4%	-99.7%	$20.26M	N/A	N/A	30	Gap Up
ZIVO ZIVO Bioscience	N/A	$4.83 flat	N/A	-69.2%	$20.05M	$15.85K	N/A	10	Gap Up
LGVN Longeveron	2.6158 of 5 stars	$0.62 -1.4%	$5.50 +783.8%	-60.4%	$19.65M	$1.20M	N/A	20	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMRA) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomerica (BMRA) Competitors

BMRA vs. ATOS, KALA, ZIVO, LGVN, and LPCN

How does Biomerica compare to Atossa Genetics?

Summary

How does Biomerica compare to KALA BIO?

Summary

How does Biomerica compare to ZIVO Bioscience?

Summary

How does Biomerica compare to Longeveron?

Summary

How does Biomerica compare to Lipocine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA vs. The Competition

Biomerica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biomerica (BMRA) Competitors

BMRA vs. ATOS, KALA, ZIVO, LGVN, and LPCN

How does Biomerica compare to Atossa Genetics?

Do analysts recommend BMRA or ATOS?

Do insiders & institutionals believe in BMRA or ATOS?

Does the media favor BMRA or ATOS?

Is BMRA or ATOS more profitable?

Which has higher earnings & valuation, BMRA or ATOS?

Which has more risk and volatility, BMRA or ATOS?

Summary

How does Biomerica compare to KALA BIO?

Do institutionals & insiders believe in KALA or BMRA?

Is KALA or BMRA more profitable?

Which has more risk and volatility, KALA or BMRA?

Do analysts rate KALA or BMRA?

Which has higher earnings & valuation, KALA or BMRA?

Does the media refer more to KALA or BMRA?

Summary

How does Biomerica compare to ZIVO Bioscience?

Do analysts recommend BMRA or ZIVO?

Is BMRA or ZIVO more profitable?

Do insiders & institutionals hold more shares of BMRA or ZIVO?

Which has stronger earnings & valuation, BMRA or ZIVO?

Does the media prefer BMRA or ZIVO?

Which has more volatility & risk, BMRA or ZIVO?

Summary

How does Biomerica compare to Longeveron?

Does the media prefer BMRA or LGVN?

Do analysts prefer BMRA or LGVN?

Do insiders and institutionals believe in BMRA or LGVN?

Which has more volatility and risk, BMRA or LGVN?

Is BMRA or LGVN more profitable?

Which has better valuation & earnings, BMRA or LGVN?

Summary

How does Biomerica compare to Lipocine?

Is BMRA or LPCN more profitable?

Which has more risk & volatility, BMRA or LPCN?

Does the media refer more to BMRA or LPCN?

Do insiders & institutionals hold more shares of BMRA or LPCN?

Which has better valuation & earnings, BMRA or LPCN?

Do analysts prefer BMRA or LPCN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA vs. The Competition

Biomerica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools